Solutions

Online Inquiry

Your Name *

Phone Number *

E-mail Address *

Services Interested *

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Vibrio Vulnificus Infection

The economic impact of Vibrio vulnificus infections on the aquaculture industry is profound, necessitating the urgent development of effective vaccines and therapeutic options. Our company prides itself on offering comprehensive vaccine and therapy development services tailored specifically for Vibrio vulnificus infections.

Overview of Vibrio Vulnificus Infection

Vibrio vulnificus, a Gram-negative, halophilic bacterium, poses a significant threat to public health, particularly in coastal regions where seafood consumption is prevalent. This pathogen is known for its rapid progression from infection to septicemia and its high fatality rate, especially among individuals with pre-existing conditions such as liver disease. The infection can be acquired through the consumption of raw or undercooked seafood and through open wounds exposed to contaminated seawater.

Reported Vibrio vulnificus cases in the United States from 1988 to 2010. Fig.1 Vibrio vulnificus cases reported in the United States, 1988-2010. (Baker-Austin, C., et al., 2018)

Bivalent Inactivated Vaccines

In the realm of veterinary vaccines, a bivalent inactivated vaccine has demonstrated promising results in turbot, a species of fish. This vaccine, which uses Montanide™ ISA 763 AVG as an adjuvant, has shown to increase survival rates and stimulate both cellular and humoral immune responses. The vaccine's efficacy is evidenced by an RPS of 77% following challenge with Aeromonas salmonicida and Vibrio vulnificus.

Multi-Epitope Peptide Vaccines

On the human front, immunoinformatics has paved the way for the design of a novel multi-epitope peptide vaccine. This in silico approach identifies potential epitope vaccine candidates, such as the proteins vibC and flgL, which have shown high affinity for the predominant HLA allele in humans. The designed vaccine construct is expected to elicit a robust immune response by targeting both B and T cell epitopes.

Therapeutics Development for Vibrio Vulnificus Infection

Antibiotic Studies

Research has focused on evaluating the efficacy of different antibiotics, including ceftriaxone, cefepime, doxycycline, and ciprofloxacin, in both in vitro and in vivo models. Combination therapies have proven to be more effective, significantly decreasing bacterial growth and improving survival rates in mouse models of intestinal infection.

Iron Sequestration Therapies

Given the dependency of V. vulnificus on iron for growth, therapies that involve the sequestration of iron have been considered. The ability of certain strains to capture iron from transferrin could be targeted to limit the bacterium's growth.

Our Services

Through our robust research infrastructure and expertise, our company is committed to driving innovative solutions and providing one-stop Vibrio vulnificus infection vaccine and therapeutic development services to global pharmaceutical companies.

Vaccine Development

Therapeutic Development

Disease Models

Iron-Dextran-Treated Mouse Models: Mice are injected intraperitoneally (i.p.) with iron dextran to increase susceptibility to V. vulnificus infection
Zebrafish (Danio rerio) Models: Immersion, intraperitoneal injection

Our preclinical research services involve the rigorous evaluation of vaccine candidates and therapeutic agents. We utilize state-of-the-art facilities and methodologies to assess the safety, efficacy, and immunogenicity of these products. If you are interested in our services, please feel free to contact us.

References

Baker-Austin, Craig, and James D. Oliver. "Vibrio vulnificus: new insights into a deadly opportunistic pathogen." Environmental microbiology 20.2 (2018): 423-430.
Wang, Jieyi, et al. "Clinical features and treatment outcomes of Vibrio vulnificus infection in the coastal city of Ningbo, China." Frontiers in Microbiology 14 (2023): 1220526.
Xiu, Yunji, et al. "Evaluation of Immune Protection of a Bivalent Inactivated Vaccine against Aeromonas salmonicida and Vibrio vulnificus in Turbot." Fishes 9.4 (2024): 131.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.